Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced the FDA approval of Requip XL in the US for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Subscribe to our email newsletter
GlaxoSmithKline’s Requip XL is said to be the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson’s disease. The product should be available in pharmacies in mid-July 2008.
Requip XL is an extended-release, once-daily tablet formulation that uses SkyePharma’s patented Geomatrix technology. This innovative tri-layer formulation allows for continuous delivery of ropinirole over 24 hours to provide smooth blood levels.
According to the company, Requip XL offers physicians and patients a simple titration regimen; it also offers a convenient, once-daily dosing schedule compared to other oral dopamine agonists, which are dosed multiple times a day.